FibroBiologics, Inc. (FBLG)
NCM · Healthcare · Biotechnology
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
About FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (5.0M) | (2.6M) | (5.1M) | (4.0M) |
| Net Income | (5.8M) | (3.2M) | (5.0M) | (4.1M) |
| Diluted EPS | $-2.60 | N/A | $-1.33 | $-0.66 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (4.5M) | (8.9M) | (13.7M) | (16.6M) |
| Net Income | (5.1M) | (16.5M) | (11.2M) | (18.6M) |
| Diluted EPS | $-3.15 | $-11.74 | $-6.80 | $-8.40 |